S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Adar1 Capital Management/Q4 2025

Adar1 Capital Management

Period: Q4 2025 Β· Filed: 2026-02-18
View on SEC EDGAR β†—
AUM
$1.36B
Total portfolio value
Positions
270
Reported securities
Top Holding
ABVX
13.1% $177.7M
QoQ Changes
+0 / -0
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2026-02-18) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
ABVXABIVAX SA$177.7M13.05%$134.85$144.65+7.3%
13.1%
PTGXPROTAGONIST THERAPEUTICS INC$91.6M6.73%$87.34$131.62+50.7%
6.7%
ROIVROIVANT SCIENCES LTD$74.4M5.46%$21.70$35.13+61.9%
5.5%
IMVTIMMUNOVANT INC$63.1M4.63%$25.42$38.79+52.6%
4.6%
RNAMAVIDITY BIOSCIENCES INC$39.4M2.90%β€”β€”
2.9%
BOXXEA SERIES TRUST$38.8M2.85%$115.10$117.22+1.8%
2.9%
SPYSPDR S&P 500 ETF TR$37.3M2.74%$678.32$744.78+9.8%
2.7%
CYTKCYTOKINETICS INC$34.3M2.52%$63.54$86.49+36.1%
2.5%
SEPNSEPTERNA INC$32.3M2.37%$27.88$34.00+21.9%
2.4%
ABUSARBUTUS BIOPHARMA CORP$26.1M1.91%$4.81$4.87+1.3%
1.9%
ZLABZAI LAB LTD$22.0M1.61%$17.64$19.12+8.4%
1.6%
TERNTERNS PHARMACEUTICALS INC$21.9M1.61%$40.40β€”
1.6%
CTMXCYTOMX THERAPEUTICS INC$17.8M1.31%$4.26$3.82-10.3%
1.3%
CLDXCELLDEX THERAPEUTICS INC NEW$17.6M1.29%$27.16$38.37+41.3%
1.3%
RAPTRAPT THERAPEUTICS INC$17.3M1.27%β€”β€”
1.3%
IKTINHIBIKASE THERAPEUTICS INC$16.5M1.21%$2.05$1.99-2.9%
1.2%
BBIOBRIDGEBIO PHARMA INC$16.3M1.20%$76.49$77.19+0.9%
1.2%
MNPRMONOPAR THERAPEUTICS INC$15.3M1.12%$65.30$97.79+49.8%
1.1%
PCVXVAXCYTE INC$14.6M1.07%$46.14$58.39+26.6%
1.1%
CRNXCRINETICS PHARMACEUTICALS IN$14.4M1.06%$46.55$42.23-9.3%
1.1%
FULCFULCRUM THERAPEUTICS INC$14.2M1.04%$11.31$3.84-66.0%
1.0%
PRTAPROTHENA CORP PLC$13.9M1.02%$9.55$9.69+1.5%
1.0%
LXEOLEXEO THERAPEUTICS INC$13.8M1.02%$9.93$4.69-52.8%
1.0%
TSHATAYSHA GENE THERAPIES INC$13.7M1.01%$5.50$6.53+18.7%
1.0%
CDTXCIDARA THERAPEUTICS INC$13.2M0.97%β€”β€”
1.0%
IVAINVENTIVA SA$12.6M0.93%$4.65$3.91-15.9%
0.9%
ESTAESTABLISHMENT LABS HLDGS INC$12.5M0.92%$72.88$89.25+22.5%
0.9%
BILSPDR SERIES TRUST$12.4M0.91%$90.07$91.44+1.5%
0.9%
REPLREPLIMUNE GROUP INC$12.1M0.89%$9.72$11.58+19.1%
0.9%
IONSIONIS PHARMACEUTICALS INC$11.6M0.85%$79.11$81.80+3.4%
0.8%

Quarter-on-Quarter Activity

New Positions

None this quarter

Exited Positions

None this quarter

Increased

None this quarter

Trimmed

None this quarter

← Back to Hedge Funds
Adar1 Capital Management Q4 2025 13F Filing β€” Holdings & Portfolio | MarketsFN